Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 1

Evaluation of the relationship between coronary slow flow phenomenon and serum magnesium levels

Pages
20–24
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In multivariate regression analysis, a serum magnesium level under 1.9 mg/dL (OR:3.33, 95% CI:1.75-6.37, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Coronary slow flow phenomenon (CSFP) is a microvascular circulation disorder.
📊
Key Findings & Data:CAG records were reassessed for CSFP and 100 patients were diagnosed as having CSFP.
💡
Conclusion & Impact:In multivariate regression analysis, a serum magnesium level under 1.9 mg/dL (OR:3.33, 95% CI:1.75-6.37, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Coronary slow flow phenomenon (CSFP) is a microvascular circulation disorder. It is known that serum magnesium has positive effects on anti-inflammation, vasodilatation and endothelial functions. This observational study investigated the association of serum magnesium levels with CSFP.Materials and Methods: Patients who had undergone coronary angiography (CAG) after noninvasive testing were included in the study. CAG records were reassessed for CSFP and 100 patients were diagnosed as having CSFP. Control subjects (n = 80) had normal coronary flow. Serum Mg levels and other biochemical parameters such as glucose, creatinine, cholesterol levels and hemoglobin samples were collected before CAG. Serum Mg values were categorized into two groups: Mg levels equal/under and above 1.9 mg/dL.Results: The mean patient age was 56.1±9.7 years; 68.9% of patients were men. Patient’s hypertension, diabetes mellitus history and smoking habits rate were similar between groups. Biochemical tests revealed lower serum magnesium levels (1.87 vs 1.95mg/dL, p=0.02) for CSFP patients and controls, respectively. In multivariate regression analysis, a serum magnesium level under 1.9 mg/dL (OR:3.33, 95% CI:1.75-6.37, p

🔖

Cite This Article

TURAN, O. E., GÜLCÜ, O., AKSAKAL, E., KARAMAN, K., DEMİRELLİ, S., CEYHAN, G., ÖZTÜRK, M., KORKMAZ, A. F. (2022). Evaluation of the relationship between coronary slow flow phenomenon and serum magnesium levels. Annals of Medical Research, Cilt: 28 - Sayı: 1, 20–24. https://ajindex.com/articles/446271

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Tambe AA, Demany MA, Zimmerman HA, et al. Angina pectoris and slow flow velocity of dye in coronary arteries--a new angiographic finding. Am Heart J 1972; 84:66-71
  2. Singh S, Kothari SS, Bahl VK. Coronary slow flow phenomenon: an angiographic curiosity. Indian Heart J 2004;56:613-7
  3. Cesar LA, Ramires JA, SerranoJunior CV, et al. Slow coronary run-off in patients with angina pectoris: clinical significance and thallium-201 scintigraphic study. Braz J Med Biol Res 1996;29:605-13
  4. Xia S, Deng SB, Wang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels 2011;26:480-6
  5. Larkin SW, Clarke JG, Keogh BE, et al. Intracoronary endothelin induces myocardial ischemia by small vessel constriction in the dog. The American journal of cardiology 1989;64:956-8
  6. Clarke JG, Davies GJ, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987;1:1057-9
  7. Camsarl A, Pekdemir H, Cicek D, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J 2003; 67:1022-8
  8. Pekdemir H, Cicek D, Camsari A, et al. The relationship between plasma endothelin-1, nitric oxide levels, and heart rate variability in patients with coronary slow flow. Ann Noninvasive Electrocardiol 2004;9:24-33
  9. Pekdemir H, Polat G, Cin VG, et al. Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow. Int J Cardiol 2004;97:35-41
  10. Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients 2015;7:8199-226
  11. Shechter M. Magnesium and cardiovascular system. Magnes Res 2010;23:60-72
  12. Griendling KK, Rittenhouse SE, Brock TA, et al. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986;261:5901-6
  13. Sontia B, Touyz RM. Role of magnesium in hypertension. Arch Biochem Biophys 2007;458:33-9
  14. Nielsen FH. Magnesium deficiency and increased inflammation: current perspectives. J Inflamm Res 2018;11:25-34
  15. Libako P, Nowacki W, Rock E, et al. Phagocyte priming by low magnesium status: input to the enhanced inflammatory and oxidative stres responses. Magnes Res 2010;23:1-4
  16. Dibaba DT, Xun P, He K. Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. Eur J Clin Nutr 2014;68:510-6
  17. Altura BM, Altur